Compare RTX & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | MRK |
|---|---|---|
| Founded | 1934 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.3B | 260.2B |
| IPO Year | N/A | N/A |
| Metric | RTX | MRK |
|---|---|---|
| Price | $183.67 | $105.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $179.36 | $111.93 |
| AVG Volume (30 Days) | 4.3M | ★ 14.0M |
| Earning Date | 01-27-2026 | 02-03-2026 |
| Dividend Yield | 1.48% | ★ 3.23% |
| EPS Growth | 38.64 | ★ 58.08 |
| EPS | 4.87 | ★ 7.56 |
| Revenue | ★ $85,988,000,000.00 | $64,235,000,000.00 |
| Revenue This Year | $8.82 | $1.98 |
| Revenue Next Year | $6.24 | $4.94 |
| P/E Ratio | $37.66 | ★ $13.93 |
| Revenue Growth | ★ 8.79 | 1.68 |
| 52 Week Low | $112.27 | $73.31 |
| 52 Week High | $188.00 | $107.59 |
| Indicator | RTX | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 63.73 |
| Support Level | $176.54 | $96.79 |
| Resistance Level | $188.00 | $107.59 |
| Average True Range (ATR) | 2.80 | 2.06 |
| MACD | 0.37 | 0.16 |
| Stochastic Oscillator | 68.28 | 77.08 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).